BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hypercholesterolemia readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Hypercholesterolemia\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07821944-1048@assetmemo.bio
DTSTAMP:20261121T004445Z
DTSTART;VALUE=DATE:20271126
DTEND;VALUE=DATE:20271127
SUMMARY:Lipfendra (Enlicitide): Phase 3 readout est. (NCT07821944)
DESCRIPTION:Lipfendra (Enlicitide)\, phase 3\, Atherosclerotic Cardiovascul
 ar Disease.\nStudy: A Clinical Study of Enlicitide (MK-0616) in Adults Wit
 h Hyperlipidemia in India (MK-0616-038)\nEstimated primary completion: 26 
 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enlici
 tide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07821944
URL:https://assetmemo.bio/drug/enlicitide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492291-1048@assetmemo.bio
DTSTAMP:20261121T004445Z
DTSTART;VALUE=DATE:20281013
DTEND;VALUE=DATE:20281014
SUMMARY:Lipfendra (Enlicitide): Phase 3 readout est. (NCT06492291)
DESCRIPTION:Lipfendra (Enlicitide)\, phase 3\, Atherosclerotic Cardiovascul
 ar Disease.\nStudy: Open-label Extension Study of Enlicitide Decanoate (MK
 -0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia
  (MK-0616-019) CORALreef Extension\nEstimated primary completion: 13 Octob
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/enlicitide#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06492
 291
URL:https://assetmemo.bio/drug/enlicitide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07058077-1048@assetmemo.bio
DTSTAMP:20261121T004445Z
DTSTART;VALUE=DATE:20331204
DTEND;VALUE=DATE:20331205
SUMMARY:Lipfendra (Enlicitide): Phase 2/3 readout est. (NCT07058077)
DESCRIPTION:Lipfendra (Enlicitide)\, phase 2/3\, Atherosclerotic Cardiovasc
 ular Disease.\nStudy: A Study of Enlicitide Decanoate (MK-0616\, an Oral P
 CSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hyp
 ercholesterolemia (MK-0616-029)\nEstimated primary completion: 4 December 
 2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/enlicitide#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07058077
URL:https://assetmemo.bio/drug/enlicitide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
